Trimetazidin belongs to a group of medicines called cardiac preparations. This is a drug for the treatment of angina pectoris. Trimetazidin protects heart cells from the effects of lack of oxygen during angina attacks.
Trimetazidin used to treat vestibular disorders / as dizziness and tinnitus /.
Do not take Tevatrim 35 mg:
If you are allergic to trimetazidin or any of the other ingredients of Tevatrim.
Take special care with Tevatrim:
Have eye problems that are caused by high blood pressure in the blood vessels of the eye or suffer from or have had glaucoma / ocular disease caused by increased pressure inside the eye /.
Have severe kidney disease.
There are no reports of interactions with other drugs.
No experience with trimetazidin during pregnancy and lactation. Trimetazidin Do not take if you are pregnant or breastfeeding, unless your doctor deems it necessary. Ask your doctor or pharmacist before taking any medicine.
This product contains 56 mg of sodium per tablet. It should be borne in mind if you are on a diet controlled salt. Talk to your doctor if you have additional questions.
The tablet should be swallowed whole with a glass of water. Do not break, crush or chew the tablets.
The usual dose is one tablet of 35 mg twice daily, one tablet in the morning and one tablet in the evening with a meal.
There is no recommended dosage for use in children. Experience in the use of this medicine in children is limited. If this medicine is for someone who is under 18, talk to your doctor if you have additional questions.
If you take more tablets than you should immediately contact your doctor.
If you forget to take a dose, just take your next dose at the usual time. Do not take a double dose to make up for a missed dose.
Take Tevatrim as long as your doctor recommends. Do not stop taking or change the dose of trimetazidin without you consult with your doctor.
Common - dizziness, headache, stomach pain, diarrhea, indigestion, nausea, vomiting, skin rash, itching or bumps.
Very rare - tremors, numbness of the hands and feet, loss of normal movement.
These symptoms will disappear after cessation of treatment.
The active substance is trimetazidinov dihydrochloride. Each prolonged-release tablet contains 35 mg trimetazidinov dihydrochloride.
The other ingredients are sodium chloride, povidone K30, magnesium stearate, cellulose acetate and hypromellose.